NCT00771030View on ClinicalTrials.gov

Study to Evaluate the Safety, PK, PD and Efficacy of AMG 827 in Adults With Rheumatoid Arthritis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 27, 2008

Primary Completion Date

May 25, 2010

Study Completion Date

May 25, 2010

Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL

Brodalumab

Solution for subcutaneous or intravenous administration

OTHER

Placebo

Solution for subcutaneous or intravenous administration

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY